OncoStem Diagnostics, a healthcare start-up for cancer patients, has raised $6 million in a funding round led by Sequoia Capital India.

In a statement, the company said that the capital raised will be used in deepening research and development efforts, besides developing and automating tests for oral, brain and colon cancer.

“There are no affordable tests in India to accurately predict the risk of cancer recurrence. We aim to develop cost-effective tests that will help predict and assess the risk of recurrence, providing doctors with an actionable blueprint for personalised treatment,” Manjiri Bakre, founder and CEO, OncoStem, said.

OncoStem Diagnostics was founded in 2011 with the vision of developing innovative multimarker prognostic and predictive tests to enable personalized treatment planning for patients with Cancer. Its mission is to become the leading Oncology Diagnostics Company of the 21st century.

Earlier, Artiman Ventures had also invested in the company.

Founded by Manjiri Bakre herself, OncoStem focuses on developing tests to identify patterns of recurrence in various cancers.

OncoStem’s long-term goal is to improve cancer treatment using precision medicine tools. Our tests have been designed and developed with the vision of being used as companion diagnostics to new targeted therapies in the future. OncoStem is currently working towards identifying and characterising novel drug targets for Breast and Oral Cancer.